drugset / Trial / NCT04689308
This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 study of MH048 in patients with selected Relapsed/Refractory B-cell Malignancies.
Timeline
- Start
- 2021-01-07
- Primary completion
- 2023-06-30
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MH048 | Unknown | 5 mg | Oral |
| Subject | MH048 | Unknown | 25 mg | Oral |